Current status of percutaneous coronary intervention with drug-eluting stents in Asia

Circulation

Volumn 118, Issue 25, 2008, Pages 2730-2737

  Park, Seung Jung ^a,b   Kim, Young Hak ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b University of Ulsan   (South Korea)

Author keywords

Angioplasty; Coronary disease; Stents

Indexed keywords

ARTICLE; ASIA; DRUG ELUTING STENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASIA; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; HUMANS;

EID: 58249131875     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.743450     Document Type: Article

References (67)

1. Serruys PW, Kutryk MJB, Ong ATL. Coronary-artery stents. N Engl J Med. 2006;354:483-495.
2. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G. Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002; 346:1773-1780.
3. Moses JW. Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS. Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003; 349:1315-1323.
4. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME, for the TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engt J Med. 2004;350: 221-231.
5. Iakovoul, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126-2130.
6. Pinto Slottow TL, Waksman R. Overview of the 2006 Food and Drug Administration Circulatory System Devices Panel meeting on drug-eluting stent thrombosis. Catheter Cardiovasc Interv. 2007;69: 1064-1074.
7. Park DW, Park SW, Park KH, Lee BK, Kim YH, Lee CW, Hong MK, Kim JJ, Park SJ. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol. 2006;98:352-356.
8. Lim YL MM. PCI in Asia-Pacific region: present and future. Available at: http://www.europcronline.com/fo/lecture/zoom_diapo.php?id=273&indice=4. Accessed September 17, 2007.
9. Cheng TO. The current state of cardiology in China. Int J Cardiol. 2004;96:425-439.
10. Fajadet J, Wijns W, Laarman G-J, Kuck K-H, Ormiston J, Munzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE, for the ENDEAVOR II Investigators. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II Trial. Circulation. 2006;114: 798-806.
11. Park S-J. Drug-eluting stent: real world experience(AMC Registry Study). Available at: http://www.summitmd.com/html/technical/coronary/ technical_coronary_slide.php?no_slide=133&no_presentation=. Accessed September 9, 2007.
12. Kimura T. One-year follow-up from the J-Cypher registry. Available at: http://www.summitmd.com/html/technical/coronary/technical_coronary_slide.php? no_slide=298&no_presentation=&title=&slidesize=4. Accessed September 9, 2007.
13. Shuchman M. Debating the risks of drug-eluting stents. N Engl J Med. 2007;356:325-328.
14. Beohar N, Davidson CJ, Kip KE, Goodreau L, Vlachos HA, Meyers SN, Benzuly KH, Flaherty JD, Ricciardi MJ, Bennett CL, Williams DO. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA. 2007;297:1992-2000.
15. Xu B, Li JJ, Yang YJ, Ma WH, Chen JL, Qiao SB, Qin XW, Yao M, Liu HB, Wu YJ, Yuan, JQ CJ, You SJ, Dai J, Xia R, Gao RL. A single center investigation of bare-metal or drug-eluting stent restenosis from 1633 consecutive Chinese Han ethnic patients. Chin Med J (Engl). 2006;119: 533-538.
16. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, Kramer JM, Harrington RA, Matchar DB, Kandzari DE, Peterson ED, Schulman KA, Califf RM. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007;297: 159-168.
17. Win HK, Caldera AE, Maresh K, Lopez J, Rihal CS, Parikh MA, Granada JF, Marulkar S, Nassif D, Cohen DJ, Kleiman NS, for the Event Registry Investigators. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA. 2007;297: 2001-2009.
18. Urban P, Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J, Seth A, Sousa JE, Wijns W, Berge C, Deme M, Stoll H-P, on behalf of the e-Cypher Investigators. Safety of coronary sirolimus-eluting stems in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation. 2006;113:1434-1441.
19. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009-1019.
20. Tu JV, Bowen J, Chiu M, Ko DT, Austin PC, He Y, Hopkins R, Tarride J-E, Blackhouse G, Lazzam C, Cohen EA, Goeree R. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med. 2007;357: 1393-1402.
21. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115: 2344-2351.
22. Machecourt J, Danchin N, Lablanche JM, Fauvel JM, Bonnet JL, Marliere S, Foote A, Quesada JL, Eltchaninoff H, Vanzetto G. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry. J Am Coll Cardiol. 2007;50:501-508.
23. Steg PG, Bhatt DL, Wilson PW, D'Agostino R Sr, Ohman EM, Rother J, Liau CS, Hirsch AT, Mas JL, Ikeda Y, Pencina MJ, Goto S. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:1197-1206.
24. Park SJ, Kim YH, Lee BK, Lee SW, Lee CW, Hong MK, Kim JJ, Mintz GS, Park SW. Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation. J Am Coll Cardiol. 2005;45:351-356.
25. Kim YH, Park SW, Hong MK, Park DW, Park KM, Lee BK, Song JM, Han KH, Lee CW, Kang DH, Song JK, Kim JJ, Park SJ. Comparison of simple and complex stenting techniques in the treatment of unprotected left main coronary artery bifurcation stenosis. Am J Cardiol. 2006;97: 1597-1601.
26. Lee BK, Hong MK, Lee CW, Choi BR, Kim MJ, Park KH, Kim YH, Han KH, Kim JJ, Park SW, Park SJ. Five-year outcomes after stenting of unprotected left main coronary artery stenosis in patients with normal left ventricular function. Int J Cardiol. 2007;115:208-213.
27. Lee SH, Ko YG, Jang Y, Kwon HM, Lee SH, Yoon JH, Park SH, Kim BO, Jeon DW, Yang JY, Ryu SK. Sirolimus- versus paclitaxel-eluting stent implantation for unprotected left main coronary artery stenosis. Cardiology. 2005;104:181-185.
28. Chieffo A, Park SJ, Valgimigli M, Kim YH, Daemen J, Sheiban I, Truffa A, Monlorfano M, Airoldi F, Sangiorgi G, Carlino M, Michev I, Lee CW, Hong MK, Park SW, Moretti C, Bonizzoni E, Rogacka R, Serruys PW, Colombo A. Favorable long-term outcome after drug-eluting stent implantation in nonbifurcation lesions that involve unprotected left main coronary artery: a multicenter registry. Circulation. 2007;116:158-162.
29. Ge L, Cosgrave J, Iakovou I, Qian JY, Agostoni P, Sangiorgi GM, Airoldi F, Michev ICA, Corvaja N, Colombo A, Ge JB. Long-term outcomes following drug-eluting stent implantation in unprotected left main bifurcation lesions. Chin Med J (Engl). 2007;120:545-551.
30. Lee RJ, Shin KN, Lee SH, Shyu KG, Chiu CZ, Lin SC, Hung HF, Liou JY, Cheng JJ, Kuan P. Predictors of long-term outcomes in patients after elective stent implantation for unprotected left main coronary artery disease. Heart Vessels. 2007;22:99-103.
31. Seung KB, Park DW, Kim YH, Lee SW, Lee CW, Hong MK, Park SW, Yun SC, Gwon HC, Jeong MH, Jang Y, Kim HS, Kim PJ, Seong IW, Park HS, Ahn T, Chae IH, Tank SJ, Chung WS, Park SJ. Stents versus coronary-artery bypass grafting for left main coronary artery disease. N Engl J Med. 2008;358:1781-1792.
32. Nakamura S, Muthusamy TS, Bae J-H, Cahyadi YH, Udayachalerm W, Tresukosol D. Impact of sirolimus-eluting stent on the outcome of patients with chronic total occlusions. Am J Cardiol. 2005;95: 161-166.
33. Jang JS, Hong MK, Lee CW, Park DW, Lee BK, Kim YH, Han KH, Kim JJ, Park SW, Park SJ. Comparison between sirolimus- and paclitaxel-eluting stents for the treatment of chronic total occlusions. J Invasive Cardiol. 2006;18:205-208.
34. Kim YH, Park SW, Lee CW, Hong MK, Gwon HC, Jang YS, Lee MM, Koo BK, Oh DJ, Seung KB, Tahk SJ, Yoon JH, Park SJ. Comparison of sirolimus-eluting stent, paclitaxel-eluting stent and bare metal stent in the treatment of long coronary lesions. Catheter Curdiovasc Interv. 2006;67: 181-187.
35. Kim YH, Park SW, Lee SW, Park DW, Yun SC, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, Lee JH, Choi SW, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Park SJ, for the Long-DES-H Study Investigators. Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. Circulation. 2006;114:2148-2153.
36. Lee CW, Park KH, Kim YH, Hong MK, Kim JJ, Park SW, Park SJ. Clinical and angiographic outcomes after placement of multiple overlapping drug-eluting stents in diffuse coronary lesions. Am J Cardiol. 2006;98:918-922.
37. Gaku N, Tanabe K, Aoki J, Onuma Y, Yamamoto H, Higashikuni Y. Nakajima H, Hara K. Clinical and angiographic outcomes of sirolimus-eluting stents implantation in Japanese patients in daily practice. Circ J. 2006;70:1367-1371.
38. Lee CW, Park DW, Lee BK, Kim YH, Hong MK, Kim JJ, Park SW, Park SJ. Predictors of restenosis after placement of drug-eluting stents in one or more coronary arteries. Am J Cardiol. 2006;97:506-511.
39. Chen JL, Gao RL, Yang YJ, Qiao SB, Qin XW, Yao M, Xu B, Liu HB, Wu YJ, Yuan JQ, Chen JWY, Dai J. Short and long-term outcomes of two drug eluting slents in bifurcation lesions, Chin Med J (Engl). 2007;120: 183-186,
40. Tsuchikane E, Aizawa T, Tamai H, Igarashi Y, Kawajiri K, Ozawa N, Nakamura S, Oku K, Kijima M, Suzuki T. Pre-drug-eluting stent debulking of bifurcated lesions: a multicenter prospective registry (PERFECT Registry). J Am Coll Cardiol. 2007;50:1941-1945.
41. Lee SW, Park SW, Park DW, Lee SW, Kim SH, Jang JS, Jeong YH, Kim YH, Lee CW, Hong MK, Yun SC, Kim JJ, Park SJ. Comparison of six-month angiographic and three-year outcomes after sirolimus-eluting stent implantation versus brachytherapy for bare metal in-stent restenosis. Am J Cardiol. 2007;100:425-430.
42. Kim YH, Lee BK, Park DW, Park KH, Choi BR, Lee CW, Hong MK, Kim JJ, Park SW, Park SJ. Comparison with conventional therapies of repeated sirolimus-eluting stent implantation for the treatment of drug-eluting coronary stent restenosis. Am J Cardiol. 2006;98: 1451-1454.
43. Yang TH, Park SW, Hong MK, Park DW, Park KM, Kim YH, Han KH, Lee CW, Cheong SS, Kim JJ, Park SJ. Impact of diabetes mellitus on angiographic and clinical outcomes in the drug-eluting stems era. Am J Cardiol. 2005;96:1389-1392.
44. Yang ZK, Shen WF, Zhang RY, Kong Y, Zhang JS, Hu J, Zhang Q, Ding FH. Coronary artery bypass surgery versus percutaneous coronary intervention with drug-eluting stent implantation in patients with multivessel coronary disease. J Interv Cardiol. 2007;20:10-16.
45. Serruys PW, Ong ATL, Morice M-C, Bruyne BD, Colombo A, Macaya C, Richardt G, Fajadet J, Hamm C, Dawkins K, O'Malley AJ, Bressers M, Donohoe D. Arterial Revascularisation Therapies Study part II: sirolimus-eluting stems for the treatment of patients with multivessel de novo coronary artery lesions. Eurointervention. 2007;1:147-156.
46. Keeley EC, Hillis LD. Primary PCI for myocardial infarction with ST-segment elevation. N Engl J Med. 2007;356:47-54.
47. Kostis WJ, Demissie K, Marcella SW, Shao Y-H, Wilson AC, Moreyra AE. The myocardial infarction data acquisition system study: weekend versus weekday admission and mortality from myocardial infarction. N Engl J Med. 2007;356:1099-1109.
48. Park CB, Lee CW, Lee BK, Kim YH, Hong MK, Kim JJ, Park SW, Park SJ. Safety and efficacy with drug-eluting stent in ST-segment elevation and non-ST-segment elevation myocardial infarction. Clin Cardiol. 2006; 29:199-203,
49. Lee JH, Kim HS, Lee SW, Park JH, Choi SW, Jeong JO, Chae JK, Ko JK, Seong IW. Randomized trial of sirolimus- versus paclitaxel-eluting stems for the treatment of acute ST-elevation myocardial infarction. J Am Coll Cardiol. 2006;47(suppl 1):184A, Abstract.
50. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol. 2005;45:2088-2092.
51. Park DW, Park SW, Lee SW, Kim YH, Lee CW, Hong MK, Kim JJ, Park SJ. Frequency of coronary arterial late angiographic stent thrombosis (LAST) in the first six months: outcomes with drug-eluting stems versus bare metal stents. Am J Cardiol. 2007;99:774-778.
52. Mutoh M, Ishikawa T, Hasuda T, Okada H, Endo A, Miyanaga S, Higashitani M, Nakano Y, Kubota T, Nakata K, Nagoshi T, Hayashi M, Sakamoto H, Oota M, Imai K, Mochizuki S. Predictors of target lesion revascularization and documented stent thrombosis beyond 30 days after sirolimus-eluting stent implantation: retrospective analysis in consecutive 1,070 angiographic follow-up lesions. Circ J. 2007;71: 1328-1331.
53. Takahashi S, Kaneda H, Tanaka S, Miyashita Y, Shiono T, Taketani Y, Domae H, Matsumi JMS, Minami Y, Sugitatsu K, Saito S. Late angiographic stent thrombosis after sirolimus-eluting stent implantation. Circ J. 2007;71:226-228.
54. Fukushima K, Kobayashj Y, Okuno T, Nakamura Y, Sakakibara M, Nakayama T, Kuroda NMA, Shimizu Y, Komuro I. Incidence of side-effects of ticlopidine after sirolimus-eluting stent implantation. Circ J. 2007;71:617-619.
55. Lee SW, Park SW, Hong MK, Kim YH, Lee BK, Song JM, Han KH, Lee CW, Kang D-H, Song JK, Kim JJ, Park SJ. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol. 2005;46:1833-1837.
56. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, Grines CL, Block E, Ghazzal ZMB, Morris DC, Liberman H, Parker K, Jurkovitz C, Murrah N, Foster J, Hyde P, Mancini GBJ, Weintraub WS, for the Cilostazol for Restenosis Trial I, Coronary stent restenosis in patients treated with cilostazol. Circulation. 2005;112:2826-2832.
57. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, Lee JH, Choi SW, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Park SJ. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long Trial). Am J Cardiol. 2007;100:1103-1108.
58. Biondi-Zoccai GG, Sangiorgi GM, Antoniucci D, Grube E, Di Mario C, Reimers B, Tamburine C, Agostoni P, Cosgrave J, Colombo A. Testing prospectively the effectiveness and safety of paclitaxel-eluting stents in over 1000 very high-risk patients: design, baseline characteristics, procedural data and in-hospital outcomes of the multicenter Taxus in Real-life Usage Evaluation (TRUE) Study. Int J Cardiol. 2007;117: 349-354.
59. Okabe T, Mintz GS, Buch AN, Roy P, Hong YJ, Smith KA, Torguson R, Gevorkian N, Xue Z, Satler LF, Kent KM, Pichard AD, Weissman NJ, Waksman R. Intravascular ultrasound parameters associated with stent thrombosis after drug-eluting stent deployment. Am J Cardiol. 2007;100: 615-620.
60. Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, Vogel R, Hess O, Meier B, Windecker S. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation. 2007;115:2426-2434.
61. Liu HB, Xu B, Qiao SB, Yang YJ, Ma WH, Qin XW, Yao M, Wu YJ, Yuan JQ, Chen J, You, SJ DJ, Xia R, Li JJ, Chen JL, Gao RL. A comparison of clinical and angiographic outcomes after Excel bioabsorbable polymer versus Firebird durable polymer rapamycin-eluting stent for the treatment of coronary artery disease in a "real world" setting: six-month follow-up results. Chin Med J (Engl). 2007; 120:574-577.
62. Bhargava B, Raju PR, Karthikeyan G, Reddy NK, Kapoor SK, Narang R, Singh C, Duggal JS, Ramamurthy S, Krishna DR, Bahl VK, Talwar KK, Raju BS. Clinical evaluation of an indigenous paclitaxel-eluting stent in de novo coronary artery stenosis. Indian Heart J. 2007;58: 38-41.
63. Bahl VK, Narang R. Current opinions on usage and regulation of drug-eluting stents in India: results of a nation-wide survey of Indian cardiologists. Indian Heart J. 2005;57:355-359.
64. Ryan J, Cohen DJ. Are drug-eluting stents cost-effective? It depends on whom you ask. Circulation. 2006;114:1745-1754.
65. Tashiro T, Morishige N, Iwahashi H, Hayashida Y, Takeuchi K, Ito N. Coronary artery bypass grafting in DES era. Ann Thorac Cardiovasc Surg. 2007;13:5-8.
66. Manabe S, Sunamori M. Radial artery graft for coronary artery bypass surgery: biological characteristics and clinical outcome. J Card Surg. 2006;21:102-114.
67. Youn YN, Chang BC, Hong YS, Kwak YL, Yoo KJ. Early and mid-term impacts of cardiopulmonary bypass on coronary artery bypass grafting in patients with poor left ventricular dysfunction: a propensity score analysis. Circ J. 2007;71:1387-1394.